title: Amantadine for weight gain associated with olanzapine treatment.
abstract: Patients with schizophrenia (Sch), schizoaffective, schizophreniform, or bipolar (BP) I disorders [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)]; not manic or acutely psychotic [Brief Psychiatric Rating Scale (BPRS) total score < or =45]; treated with olanzapine for 1-24 months; and who had gained > or =5% of their initial body weight were examined to determine whether amantadine could attenuate weight gain or promote weight loss. Olanzapine (Olz; 5-20 mg/day) was co-administered with double-blind treatment of 100-300 mg/day amantadine (Olz+Amt, n=60) or placebo (Olz+Plc, n=65). Visit-wise analysis of weight showed that weight change from baseline [last-observation-carried-forward (LOCF)] in the Olz+Amt group was significantly different from the Olz+Plc group at weeks 8 (P=0.042), 12 (P=0.029), and 16 (primary endpoint, mean+/-S.D.: -0.19+/-4.58 versus 1.28+/-4.26 kg, P=0.045). Mean BPRS total score, positive subscale, and anxiety-depression scores improved comparably in both groups, and Montgomery-Asberg Depression Rating Scale (MADRS) total score improved in the Olz+Amt group. Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy.
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA. deberdt_walter@lilly.com
authors.forename: Walter
authors.initials: W
authors.lastname: Deberdt
authors.forename: Andrew
authors.initials: A
authors.lastname: Winokur
authors.forename: Patrizia A
authors.initials: PA
authors.lastname: Cavazzoni
authors.forename: Quynh N
authors.initials: QN
authors.lastname: Trzaskoma
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Carlson
authors.forename: Frank P
authors.initials: FP
authors.lastname: Bymaster
authors.forename: Karen
authors.initials: K
authors.lastname: Wiener
authors.forename: Michel
authors.initials: M
authors.lastname: Floris
authors.forename: Alan
authors.initials: A
authors.lastname: Breier
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000547:Amantadine / Q000494:pharmacology / Q000627:therapeutic use*; D000704:Analysis of Variance; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D003710:Demography; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000145:classification / Q000188:drug therapy; D008875:Middle Aged; D000077152:Olanzapine; D013997:Time Factors; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000547:Amantadine; D000077152:Olanzapine